Круглосуточно

+7 (965) 177 17 74


бесплатно по России
cbc40e52
img

цаталодж 3055290

img

The current COVID-19 pandemic caused by SARS-CoV-2 has become a global health emergency. Treatment of chronic inflammatory bowel disease (CIBD) according to the standards includes the use of 5-aminosalicylic acid (5-ASA), corticosteroids, cytostatics, and biological therapy. However, these treatments can weaken the immune system, which potentially puts COPD patients at increased risk of infections and infectious diseases, including COVID-19. Therefore, patients with CVD have a greater risk of developing COVID-19 and more severe clinical course, or even death, compared to the general population.

Moreover, low vitamin D levels common in patients with CVD may increase the risk and severity of COVID-19. This is because vitamin D increases levels of anti-inflammatory cytokines and reduces viral replication, which in turn can reduce pro-inflammatory cytokines that contribute to lung damage. Despite the lack of evidence demonstrating increased susceptibility to COVID-19, drugs used in the treatment of COPD increase the risk of respiratory tract infections to varying degrees. However, theoretically, some immunosuppressive drugs may have beneficial effects, given that the cause of death in COVID-19 is a cytokine storm leading to acute respiratory failure.

On March 11, 2020, the World Health Organization declared the novel severe respiratory syndrome coronavirus (SARS-CoV-2) a pandemic. The number of cases worldwide is constantly growing, the infection is a serious threat to health, especially in the case of old age, immunodeficiency and the presence of concomitant diseases. There are now a growing number of reports and preliminary observations indicating that the COVID-19 virus can also infect the skin. Skin lesions ranging from "covid fingers" to hives can be potential signs of coronavirus. The flow of information about the skin manifestations of coronavirus infection prompts the development of a classification of these lesions.

img

Именно переход на использование в Украине ИПВ для всех доз Календаря прививок должен быть ближайшей задачей по вакцинопрофилактике. Для этого можно использовать несколько механизмов, включая гуманитарную помощь, заключение планируемых прямых договоров с производителями вакцин исходя из потребностей необходимого состава вакцин согласно Календарю, в частности с учетом существования современных комбинированных вакцин с ИПВ, которые могут быть использованы и в более старшем возрасте. При отсутствии комбинированных вакцин с ИПВ можно использовать ИПВ в качестве моновакцины.


Контакты
  • г. Москва,
  • м. Отрадное,
  • Высоковольтный проезд, д. 1, к. 7

+7 (965) 177 17 74

  • Режим работы:

10:00 до 20:00 пн-пт

10:00 до 18:00 сб-вс

Забор анализов:

9:00 до 20:00 пн-пт

9:00 до 18:00 сб-вс